A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
NCT04927065 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 5161
Last updated 2025-02-28
Summary
This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as booster doses.
Conditions
Interventions
- BIOLOGICAL
-
mRNA-1273.211
Sterile liquid for injection
- BIOLOGICAL
-
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1273.617.2
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1273.213
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1273.529
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1273.214
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1273.222
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1273.815
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1273.231
Sterile liquid for injection
Sponsors & Collaborators
-
ModernaTX, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-05-28
- Primary Completion
- 2023-11-17
- Completion
- 2023-11-17
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
NCT05541861 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
NCT05004181 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
NCT05975060 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
NCT04649151 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
NCT05249816 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
NCT05477186 ·Status: COMPLETED ·Phase: PHASE1
-
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
NCT05279365 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
NCT04999111 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
NCT05197153 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
NCT05345873 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
NCT05602961 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
NCT04813796 ·Status: COMPLETED ·Phase: PHASE1
-
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
NCT04889209 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
NCT04713553 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
NCT05212610 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.
NCT05330871 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
NCT04785144 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine
NCT05492643 ·Status: UNKNOWN ·Phase: NA
-
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
NCT05148962 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
NCT05995275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
NCT04904549 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
NCT05367908 ·Status: COMPLETED
-
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
NCT03392389 ·Status: COMPLETED ·Phase: PHASE1